Brexpiprazole Oral Suspension(Loncom Pharma)

布瑞哌唑口服混悬液（朗诺制药）

Report date: 2026/01/22 11:00:09

Base Information

Drug NameBrexpiprazole Oral Suspension(Loncom Pharma)
Drug Alias Namebrexpiprazol布瑞哌唑brexpiprazole依匹哌唑brexpiprazolum +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsSerotonin 1a (5-HT1a) receptor agonistsDopamine D2 receptor agonists
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D2 receptor
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaDiscontinued
Originator CompaniesShandong Loncom Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShandong Loncom Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG